X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the collaboration with Targovax, Agenus will supply QS-21 STIMULON and scientific support for up to three initial TG01 clinical trials in different cancer indications.
Lead Product(s): Apricoxib,Stimulon
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: UndisclosedProduct Type: Vaccine
Partner/Sponsor/Collaborator: Agenus
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 07, 2022
Details:
With the support from Innovation Norway, Targovax has move the TG program forward faster and more broadly, and thus bring benefit to a patient group with poor prognosis and few available treatment options.
Lead Product(s): Apricoxib,Gemcitabine
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: Phase I/ Phase IIProduct Type: Vaccine
Partner/Sponsor/Collaborator: Innovation Norway
Deal Size: $0.9 million Upfront Cash: Undisclosed
Deal Type: Funding January 12, 2022
Details:
The patent covers the use of ONCOS-102 in combination with chemotherapy in malignant pleural mesothelioma. ONCOS-102, is a genetically modified oncolytic adenovirus, which has been engineered to selectively infect cancer cells and activate the immune system.
Lead Product(s): ONCOS-102,Cisplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 24, 2021
Details:
The US FDA has granted Fast Track designation to ONCOS-102 based on the current pre-clinical and clinical data package, including mechanistic evidence showing an association between ONCOS-102-induced immune activation and tumor responses.
Lead Product(s): ONCOS-102,Pembrolizumab,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 24, 2021
Details:
ONCOS-102, an immune activators used in combination with Standard of Care (SoC) chemotherapy in patients with malignant pleural mesothelioma clearly shown tumor responses and survival outcomes.
Lead Product(s): ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 14, 2021
Details:
The study is an open-label, exploratory phase 1/2 trial adding ONCOS-102 to SoC chemotherapy (pemetrexed/cisplatin) in first- and second- (or later) line MPM to assess safety, immune activation and clinical efficacy compared with SoC alone.
Lead Product(s): ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 10, 2021
Details:
The trial is an open label, exploratory phase I/II trial adding ONCOS-102 to standard of care (SoC) chemotherapy (pemetrexed/cisplatin) in first and second (and later) line MPM to assess safety, immune activation and clinical efficacy vs SoC only.
Lead Product(s): ONCOS-102,Carboplatin,Cyclophosphamide
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Theradex
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 23, 2021
Details:
Targovax has granted an extension of 3 months to the exclusive option agreement with IOVaxis Therapeutics of Nantong, China, for clinical development and licensing of the Targovax mutant RAS vaccines TG01 and TG02 in China, Hong Kong, Macau and Singapore.
Lead Product(s): Apricoxib
Therapeutic Area: Oncology Product Name: TG01
Highest Development Status: IND EnablingProduct Type: Vaccine
Partner/Sponsor/Collaborator: IOVaxis Therapeutics
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement January 06, 2021
Details:
An 18-month analysis shows that median Overall Survival (mOS) will be at least 18.2 months for first-line patients receiving ONCOS-102 plus chemotherapy, compared to mOS of 14.2 months or less in the chemotherapy-only control group.
Lead Product(s): ONCOS-102,Cisplatin,Pemetrexed
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 24, 2020
Details:
The study is a phase I/II trial assessing the combination of intra-peritoneally delivered ONCOS-102 in combination with systemically administered durvalumab, in patients with colorectal or platinum-resistant ovarian cancers that have metastasized to the peritoneal cavity.
Lead Product(s): ONCOS-102,Durvalumab
Therapeutic Area: Oncology Product Name: ONCOS-102
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
